CINECA IRIS Institutional Research Information System

MASI, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.490
EU - Europa 6.498
AS - Asia 2.620
AF - Africa 261
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 5
Totale 25.897
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.022
IT - Italia 2.539
CN - Cina 1.237
SE - Svezia 1.191
BG - Bulgaria 749
SG - Singapore 574
DE - Germania 511
CA - Canada 463
UA - Ucraina 394
GB - Regno Unito 302
TR - Turchia 283
VN - Vietnam 283
FI - Finlandia 232
CH - Svizzera 204
CI - Costa d'Avorio 177
RU - Federazione Russa 97
FR - Francia 89
HK - Hong Kong 87
IN - India 73
AT - Austria 61
SN - Senegal 46
NG - Nigeria 34
PL - Polonia 32
BE - Belgio 23
KR - Corea 18
PK - Pakistan 18
JP - Giappone 17
CZ - Repubblica Ceca 16
NL - Olanda 16
ES - Italia 10
AU - Australia 9
EU - Europa 7
IL - Israele 7
IR - Iran 7
NZ - Nuova Zelanda 6
DK - Danimarca 5
MY - Malesia 5
EG - Egitto 4
PT - Portogallo 4
BR - Brasile 3
GR - Grecia 3
IE - Irlanda 3
LU - Lussemburgo 3
PA - Panama 3
RO - Romania 3
EE - Estonia 2
LV - Lettonia 2
MX - Messico 2
NP - Nepal 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
KH - Cambogia 1
NO - Norvegia 1
PH - Filippine 1
SM - San Marino 1
Totale 25.897
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.005
Ann Arbor 1.916
Houston 1.476
Fairfield 1.434
Chandler 1.205
Milan 1.010
Ashburn 840
Sofia 748
Seattle 662
Jacksonville 595
Cambridge 573
Wilmington 563
New York 516
Ottawa 450
Beijing 386
Princeton 311
Lawrence 298
Izmir 278
Medford 266
Nanjing 261
Serra 243
Bern 198
Dearborn 181
Abidjan 177
Singapore 164
Florence 132
Pisa 129
Des Moines 125
Dong Ket 110
Nanchang 106
Jüchen 102
Rome 101
San Diego 92
Redwood City 84
Düsseldorf 79
Hong Kong 77
Ogden 67
London 63
Vienna 61
Los Angeles 60
Boardman 59
Kunming 59
Shenyang 53
Boulder 50
Bremen 49
Dakar 46
Hebei 46
Lancaster 42
Changsha 36
Tianjin 36
Norwalk 35
Lagos 33
Warsaw 31
Hefei 30
Jiaxing 28
Seacroft 28
Shanghai 28
Genoa 26
Pune 25
Auburn Hills 23
Frankfurt am Main 22
Kent 22
Brussels 21
Orange 21
Guangzhou 20
Washington 20
Hangzhou 19
Multan 18
Phoenix 17
Hyderabad 16
Chengdu 15
Marseille 15
Jinan 14
Lappeenranta 13
Detroit 12
Westminster 12
Vicopisano 11
Bologna 10
Castiglione Chiavarese 10
Falls Church 10
Naples 10
San Giuliano Terme 10
Positano 9
Turin 9
Verona 9
Walnut 9
Xian 9
Capannori 8
Center 8
Chicago 8
Gargallo 8
Grafing 8
Groningen 8
Lanzhou 8
Fuzhou 7
Indiana 7
San Francisco 7
Zhengzhou 7
Auckland 6
Livorno 6
Totale 20.386
Salva come PNG Salva come JPEG
Nome #
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 187
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach 179
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 158
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 150
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 150
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 149
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer 148
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group 146
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 146
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 144
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine 143
FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis 140
Optimal approach to potentially resectable liver metastases from colorectal cancer 140
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study 136
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 136
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? 136
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 135
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) 134
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 133
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 133
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 132
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 131
TAS-102 for the treatment of metastatic colorectal cancer 131
Palliative treatment of unresectable metastatic colorectal cancer 130
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 130
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 130
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 129
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 128
Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer 127
null 127
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 126
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 125
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 125
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 125
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 124
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 124
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 123
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 123
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 122
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 121
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 121
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 120
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 120
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 119
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 117
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 117
CETUXIMAB RECHALLENGE IN METASTATIC COLORECTAL CANCER PATIENTS: HOW TO COME AWAY FROM ACQUIRED RESISTENCE? 116
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy 115
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 115
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice 114
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line folfoxiri 114
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI 114
Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI 113
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 113
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (pts) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 112
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 112
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 112
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 112
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial 112
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 111
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) 110
Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right? 110
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 110
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 110
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 108
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 108
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 108
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 108
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 108
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.) 107
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? 107
Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 106
Oral doxifluridine in advanced hepatocellular carcinoma: a phase II study 106
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 106
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 106
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 105
LIVER METASTASES FROM COLORECTAL CANCER: HOW TO BEST COMPLEMENT MEDICAL TREATMENT WITH SURGICAL APPROACHES. 105
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 105
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable colorectal cancer 104
Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 104
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 104
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 104
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 104
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 104
Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer 103
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 103
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 103
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 103
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts) 102
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target 102
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed 102
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 102
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 102
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 102
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 101
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 101
Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO) 100
Optimal strategy to increase the respectability of liver/lung metastases 99
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment 99
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer. 99
Totale 11.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.032
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.032
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.455 603 389 302 258 427 475 506 312 471 247 382 83
2020/20212.509 219 136 114 107 287 261 182 206 240 178 175 404
2021/20222.900 34 186 93 151 550 470 41 112 117 119 211 816
2022/20233.584 428 365 218 293 456 507 37 271 685 21 264 39
2023/20244.190 521 535 530 324 582 614 285 150 78 85 141 345
2024/202573 73 0 0 0 0 0 0 0 0 0 0 0
Totale 26.466